Physician Assistant Program year 2023 Reported 2021–2023 Source: CMS Open Payments, 2026 publication

Gennady Nosovitsky

Physician Assistant, Medical Cathedral City, CA Physician Assistant

NPI 1780007708 CMS profile 11093113

68555 Ramon Rd, Suite D103 & D104, Cathedral City, CA 92234

Open in the dashboard

General payments

$2,239

72 records reported · program years 2021–2023

Research payments

$0

Paid to them · None reported · program years 2021–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Gennady Nosovitsky of Cathedral City, CA is reported in the CMS Open Payments database as having received $2,239 across 72 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $124 6
2022 General $684 35
2021 General $1,431 31

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gennady Nosovitsky
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Gennady Nosovitsky were reported at $0. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Gennady Nosovitsky Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,431 $156 $41–$563 $132
2022 $684 $185 $55–$649 $149
2023 $124 $199 $58–$717 $160
2024 $0 $206 $62–$740 $164
2025 $0 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2023
  1. ViiV Healthcare Company $1,020 19 payments
  2. AbbVie, Inc. $349 12 payments
  3. Gilead Sciences, Inc. $184 9 payments
  4. Janssen Biotech, Inc. $147 9 payments
  5. EMD Serono, Inc. $107 6 payments
  6. Janssen Products, LP $99 1 payment
  7. Antares Pharma, Inc. $96 4 payments
  8. Napo Pharmaceuticals Inc $52 3 payments
  9. Theratechnologies Inc. $43 2 payments
  10. Amarin Pharma Inc. $31 2 payments
  11. Other $111 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2023
  1. Food and Beverage $1,299 67 payments
  2. Consulting Fee $775 1 payment
  3. Education $147 3 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $17 1 payment
Products named General payments · program years 2021–2023
  1. RUKOBIA $796 2 payments
  2. MAVYRET $333 11 payments
  3. SYMTUZA $246 10 payments
  4. CABENUVA $119 7 payments
  5. DOVATO $105 10 payments
  6. Mytesi $52 3 payments
  7. XYOSTED testosterone replacement therapy $49 2 payments
  8. XYOSTED testosterone replacement therapy $47 2 payments
  9. NOCDURNA $47 2 payments
  10. Vascepa $31 2 payments
  11. Other $303 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 150 drugs

Part D claims

9,037

Median for Physician Assistant: 241

Drug cost

$6,754,772

Median for Physician Assistant: $4,110

Branded share of claims

51.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tivicay Dolutegravir Sodium Brand 479 $1,313,421
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 298 $1,190,417
Rukobia Fostemsavir Tromethamine Brand 113 $965,572
Pifeltro Doravirine Brand 395 $681,348
Descovy Emtricitabine/Tenofov Alafenam Brand 234 $536,770
Dovato Dolutegravir Sodium/Lamivudine Brand 145 $451,741
Maraviroc Generic 171 $162,050
Cabenuva Cabotegravir/Rilpivirine Brand 26 $158,701
Xyosted Testosterone Enanthate Brand 212 $134,416
Mounjaro Tirzepatide Brand 118 $131,853

The 10 drugs with the highest cost, of 150 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Records

72 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record